MEDINDIA
English
हिन्दी
Español
français
中文
Email
3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Metaraminol.
Acebutolol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Acebutolol.
Acepromazine
Acepromazine may decrease the vasoconstricting activities of Metaraminol.
Alfuzosin
Alfuzosin may decrease the vasoconstricting activities of Metaraminol.
Amineptin
Amineptine may increase the vasopressor activities of Metaraminol.
Amitriptyline
Amitriptyline may increase the vasopressor activities of Metaraminol.
Amoxapine
Amoxapine may increase the vasopressor activities of Metaraminol.
Amphetamine
Amphetamine may increase the hypertensive activities of Metaraminol.
Aripiprazole
Aripiprazole may decrease the vasoconstricting activities of Metaraminol.
Asenapine
Asenapine may decrease the vasoconstricting activities of Metaraminol.
Atomoxetine
Atomoxetine may increase the hypertensive activities of Metaraminol.
Benzphetamine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Benzphetamine.
Benzylpenicilloyl polylysine
Metaraminol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
Brexpiprazole
Brexpiprazole may decrease the vasoconstricting activities of Metaraminol.
Bromocriptine
Bromocriptine may increase the hypertensive activities of Metaraminol.
Bunazosin
Bunazosin may decrease the vasoconstricting activities of Metaraminol.
Butriptyline
Butriptyline may increase the vasopressor activities of Metaraminol.
Cabergoline
Cabergoline may increase the hypertensive activities of Metaraminol.
Carvedilol
Carvedilol may decrease the vasoconstricting activities of Metaraminol.
Celiprolol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Celiprolol.
Chlorpromazine
Chlorpromazine may decrease the vasoconstricting activities of Metaraminol.
Clenbuterol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Clenbuterol.
Clomipramine
Clomipramine may increase the vasopressor activities of Metaraminol.
Clozapine
Clozapine may decrease the vasoconstricting activities of Metaraminol.
Dapiprazole
Dapiprazole may decrease the vasoconstricting activities of Metaraminol.
Desipramine
Desipramine may increase the vasopressor activities of Metaraminol.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Metaraminol.
Dextroamphetamine
Dextroamphetamine may decrease the vasoconstricting activities of Metaraminol.
Dihydroergocornine
Dihydroergocornine may increase the hypertensive activities of Metaraminol.
Dihydroergocristine
Dihydroergocristine may increase the hypertensive activities of Metaraminol.
Dihydroergotamine
Dihydroergotamine may increase the hypertensive activities of Metaraminol.
Dobutamine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Dobutamine.
Dopamine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Dopamine.
Dothiepin
Dosulepin may increase the vasopressor activities of Metaraminol.
Doxazosin
Doxazosin may decrease the vasoconstricting activities of Metaraminol.
Doxepin
Doxepin may increase the vasopressor activities of Metaraminol.
Dronedarone
Dronedarone may decrease the vasoconstricting activities of Metaraminol.
Droperidol
Droperidol may decrease the vasoconstricting activities of Metaraminol.
Duloxetine
Duloxetine may increase the tachycardic activities of Metaraminol.
Ephedrine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Ephedrine.
Epinephrine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Epinephrine.
ergoloid mesylates, USP
Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Metaraminol.
Ergonovine
Ergonovine may increase the hypertensive activities of Metaraminol.
Ergotamine
Ergotamine may increase the hypertensive activities of Metaraminol.
Escitalopram
Escitalopram may decrease the vasoconstricting activities of Metaraminol.
Etilefrine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Etilefrine.
Fenoterol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Fenoterol.
Fentanyl
The serum concentration of Fentanyl can be decreased when it is combined with Metaraminol.
Flupenthixol
Flupentixol may decrease the vasoconstricting activities of Metaraminol.
Furazolidone
Furazolidone may increase the hypertensive activities of Metaraminol.
Hyaluronidase
Hyaluronidase may increase the vasoconstricting activities of Metaraminol.
Hyaluronidase, Ovine
Hyaluronidase may increase the vasoconstricting activities of Metaraminol.
Iloperidone
Iloperidone may decrease the vasoconstricting activities of Metaraminol.
Imipramine
Imipramine may increase the vasopressor activities of Metaraminol.
Indoramin
Indoramin may decrease the vasoconstricting activities of Metaraminol.
Iproniazid
Iproniazid may increase the hypertensive activities of Metaraminol.
Isocarboxazid
Isocarboxazid may increase the hypertensive activities of Metaraminol.
Isoproterenol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Isoprenaline.
Isoxsuprine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Isoxsuprine.
Labetalol
Labetalol may decrease the vasoconstricting activities of Metaraminol.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Metaraminol.
Linezolid
Linezolid may increase the hypertensive activities of Metaraminol.
Lisdexamfetamine
Lisdexamfetamine may decrease the vasoconstricting activities of Metaraminol.
Lisdexamfetamine Dimesylate
Lisdexamfetamine may decrease the vasoconstricting activities of Metaraminol.
Lisuride
Lisuride may increase the hypertensive activities of Metaraminol.
MELITRACEN
Melitracen may increase the vasopressor activities of Metaraminol.
Mephentermine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Mephentermine.
Metaproterenol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Orciprenaline.
Metergoline
Metergoline may increase the hypertensive activities of Metaraminol.
Methamphetamine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Methamphetamine.
Methotrimeprazine
Methotrimeprazine may decrease the vasoconstricting activities of Metaraminol.
Methoxamine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Methoxamine.
Methylene blue
Methylene blue may increase the hypertensive activities of Metaraminol.
Methylergonovine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Metaraminol.
Methysergide
Methysergide may increase the hypertensive activities of Metaraminol.
Midodrine
The risk or severity of adverse effects can be increased when Midodrine is combined with Metaraminol.
Milnacipran
Milnacipran may increase the tachycardic activities of Metaraminol.
Minaprine
Minaprine may increase the hypertensive activities of Metaraminol.
Moclobemide
Moclobemide may increase the hypertensive activities of Metaraminol.
Nabilone
Nabilone may increase the tachycardic activities of Metaraminol.
Nefazodone
Nefazodone may decrease the vasoconstricting activities of Metaraminol.
Nialamide
Nialamide may increase the hypertensive activities of Metaraminol.
Nicardipine
Nicardipine may decrease the vasoconstricting activities of Metaraminol.
Nicergoline
Nicergoline may increase the hypertensive activities of Metaraminol.
Norepinephrine
The risk or severity of adverse effects can be increased when Norepinephrine is combined with Metaraminol.
Nortriptyline
Nortriptyline may increase the vasopressor activities of Metaraminol.
Nylidrin
The risk or severity of adverse effects can be increased when Metaraminol is combined with Nylidrin.
Olanzapine
Olanzapine may decrease the vasoconstricting activities of Metaraminol.
Opipramol
Opipramol may increase the vasopressor activities of Metaraminol.
Oxymetazoline
The risk or severity of adverse effects can be increased when Metaraminol is combined with Oxymetazoline.
p-Hydroxyamphetamine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Hydroxyamphetamine.
Paliperidone
Paliperidone may decrease the vasoconstricting activities of Metaraminol.
Pargyline
Pargyline may increase the hypertensive activities of Metaraminol.
Pergolide
Pergolide may increase the hypertensive activities of Metaraminol.
Periciazine
Propericiazine may decrease the vasoconstricting activities of Metaraminol.
Phenelzine
Phenelzine may increase the hypertensive activities of Metaraminol.
Phenmetrazine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Phenmetrazine.
Phenoxybenzamine
Phenoxybenzamine may decrease the vasoconstricting activities of Metaraminol.
Phentermine
The risk or severity of adverse effects can be increased when Phentermine is combined with Metaraminol.
PHENTERMINE RESIN
The risk or severity of adverse effects can be increased when Phentermine is combined with Metaraminol.
Phentolamine
Phentolamine may decrease the vasoconstricting activities of Metaraminol.
Phentolamine Mesylate
Phentolamine may decrease the vasoconstricting activities of Metaraminol.
Phenylephrine
The risk or severity of adverse effects can be increased when Phenylephrine is combined with Metaraminol.
Phenylpropanolamine
The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Metaraminol.
Pizotyline
Pizotifen may decrease the vasoconstricting activities of Metaraminol.
Prazosin
Prazosin may decrease the vasoconstricting activities of Metaraminol.
Procaine
Procaine may increase the hypertensive activities of Metaraminol.
Procarbazine
Procarbazine may increase the hypertensive activities of Metaraminol.
Procaterol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Procaterol.
Promazine
Promazine may decrease the vasoconstricting activities of Metaraminol.
Propiomazine
Propiomazine may decrease the vasoconstricting activities of Metaraminol.
Propiverine
Propiverine may decrease the vasoconstricting activities of Metaraminol.
Protriptyline
Protriptyline may increase the vasopressor activities of Metaraminol.
Pseudoephedrine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Pseudoephedrine.
Quetiapine
Quetiapine may decrease the vasoconstricting activities of Metaraminol.
Quetiapine fumarate
Quetiapine may decrease the vasoconstricting activities of Metaraminol.
Quinidine
Quinidine may decrease the vasoconstricting activities of Metaraminol.
Racepinephrine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Racepinephrine.
Rasagiline
Rasagiline may increase the hypertensive activities of Metaraminol.
Risperidone
Risperidone may decrease the vasoconstricting activities of Metaraminol.
Ritodrine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Ritodrine.
Selegiline
Selegiline may increase the hypertensive activities of Metaraminol.
Silodosin
Silodosin may decrease the vasoconstricting activities of Metaraminol.
Spironolactone
Spironolactone may decrease the vasoconstricting activities of Metaraminol.
Synephrine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Synephrine.
Tamsulosin
Tamsulosin may decrease the vasoconstricting activities of Metaraminol.
Tedizolid
Tedizolid Phosphate may increase the hypertensive activities of Metaraminol.
Tedizolid Phosphate
Tedizolid Phosphate may increase the hypertensive activities of Metaraminol.
Terazosin
Terazosin may decrease the vasoconstricting activities of Metaraminol.
Terbutaline
The risk or severity of adverse effects can be increased when Metaraminol is combined with Terbutaline.
Terbutaline Sulfate
The risk or severity of adverse effects can be increased when Metaraminol is combined with Terbutaline.
Tetrahydrocannabinol
Dronabinol may increase the tachycardic activities of Metaraminol.
Tetrahydrozoline
The risk or severity of adverse effects can be increased when Metaraminol is combined with Tetryzoline.
Thioproperazine
Thioproperazine may decrease the vasoconstricting activities of Metaraminol.
Thioridazine
Thioridazine may decrease the vasoconstricting activities of Metaraminol.
Tianeptine
Tianeptine may increase the vasopressor activities of Metaraminol.
Tolazoline
Tolazoline may decrease the vasoconstricting activities of Metaraminol.
Toloxatone
Toloxatone may increase the hypertensive activities of Metaraminol.
Tramazoline
The risk or severity of adverse effects can be increased when Metaraminol is combined with Tramazoline.
Tranylcypromine
Tranylcypromine may increase the hypertensive activities of Metaraminol.
Trazodone
Trazodone may decrease the vasoconstricting activities of Metaraminol.
Trifluoperazine
Trifluoperazine may decrease the vasoconstricting activities of Metaraminol.
Trimipramine
Trimipramine may increase the vasopressor activities of Metaraminol.
Tyramine
The risk or severity of adverse effects can be increased when Metaraminol is combined with Tyramine.
Urapidil
Urapidil may decrease the vasoconstricting activities of Metaraminol.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Metaraminol.
Verapamil
Verapamil may decrease the vasoconstricting activities of Metaraminol.
Ziprasidone
Ziprasidone may decrease the vasoconstricting activities of Metaraminol.
Zuclopenthixol
Zuclopenthixol may decrease the vasoconstricting activities of Metaraminol.
